Kathy McGroddy-Goetz is the Head of Strategic Partnerships at Medidata Solutions. She is responsible for managing strategic collaborations with key industry leaders to transform clinical trials for patients, sites and sponsors.
Dr. McGroddy-Goetz joined Medidata after a 26 year career at IBM innovating at the intersection of advanced technologies and new business models, with an emphasis on Healthcare and Life Sciences solutions. She spent two years as Director of Corporate Technology, leading IBM’s technology strategy, and has significant expertise in developing innovative medical imaging solutions. She played a critical role in the corporation’s launch of Watson Health, called a “moon shot” by CRO Ginni Rometty and led the Global Strategic Partnerships & Alliances team for Watson Health for three years.
Dr. McGroddy-Goetz earned a BS in physics from SUNY Binghamton and a PhD in molecular biophysics from Cornell University, where she studied protein-ligand interactions using NMR spectroscopy and molecular dynamics simulations. She holds five patents and is a frequent speaker at industry and technology conferences.
Healthcare Consumerism & Preventive Care
Pothik Chatterjee, MBA
Executive Director, Innovation & Research at LifeBridge Health
Pothik Chatterjee serves as the Executive Director of Innovation and Research at LifeBridge Health, overseeing Innovation, Research and BioIncubator programs. His oversight includes digital health, patient access and biomedical research. His team explores digital health partnerships and tech solutions to operational challenges in access and communication between patients and care providers. He supports translational research initiatives and engagement with industry sponsors in pharma and biotech. Pothik’s prior experience includes healthcare strategy with the Harvard Health System in Boston, MA, where he served as the Director of Strategic Operations for Brigham Health. Pothik earned his M.B.A from Harvard Business School and B.S. in Economics from Georgetown University.
Caroline Popper, M.D. MPH
Co-Founder and President of Popper and Company
Caroline Popper, M.D. MPH is the Co-Founder and President of Popper and Company, a Baltimore-based life sciences strategy firm, focused on companies that generate information to make healthcare better or more efficient. These include diagnostics and device product and service companies, pharma companies that manage the whole “disease” (and try to do so with increases “precision”) and consumer companies that see the patient as the central stakeholder accessing information. Caroline completed her residencies in internal medicine and pathology at Hopkins . Trained further in health economics and health policy, she consults frequently on issues pertaining to cost–effectiveness of new technology, impact of diagnostics on therapeutic use and impact on total cost of episode of care and how these drive reimbursement strategies. She has extensive experience in the diagnostics industry and has held executive positions in Fortune 500 as well as private companies. With Ken Walz she has advises several private companies in the sector on their M&A activities and led the implementation of these strategies
Gracelyn McDermott, M.B.A.
Executive Director at Kaiser Permanente
Gracelyn A. McDermott, Executive Director of Account Management at Kaiser Permanente of the Mid-Atlantic States is an innovative and diverse executive with over 20 years’ experience in Project, Program and Account Management. Kaiser Permanente is recognized as one of America’s leading health care providers and not-for-profit health plans. In her role at Kaiser Permanente, Gracelyn is responsible for retention and growth of commercial accounts in Maryland, Northern Virginia, and the District of Columbia.
Gracelyn’s overall professional career includes sales, operations and information technology leadership in the health care environment.
Prior to joining KP, Ms. McDermott served as Vice President of Accrediting & Client Services at URAC, an independent health care accrediting organization. In this role, she oversaw all aspects of the accreditation process from applicant preparation and submission through to the independent accreditation decision. Ms. McDermott also served as the Director, Specimen Administration for Ameritox, LLC, formerly a leader in pain medication monitoring, offering laboratory services and practice management tools to help clinicians coordinate and optimize the care of chronic pain patients. In this capacity, she built a new department within the organization, providing management oversight of over 350 Specimen Processors and 50 Third Party Collection sites.
Previous responsibilities include oversight of program and account management for The McConnell Group, Inc., a biodefense, biomedical and health science company, providing a comprehensive selection of professional and technical services to the government sector. She also held a series of roles with progressive program management responsibility, culminating as Vice President of Scientific Services for ICON Development Solutions, a contract research organization. In this role, Ms. McDermott managed a department of about 250 staff comprised of Project Management, Biostatistics, Data Management, SAS Programming, Clinical Operations, Pharmacokinetics, Pharmacodynamics, Modeling and Simulation – all in support of Clinical Trial Management.
Ms. McDermott holds a M.B.A. from Johns Hopkins University in Baltimore, MD. She is a certified Project Management Professional (PMP) and a member of Leadership Maryland, Class of 2018. She also serves on the Executive Board for the Maryland Chamber of Commerce; and, serves as Secretary of the Board of Trustees for her undergraduate alma mater, Mount Saint Mary’s University. She resides in Mount Airy, MD.
Santosh Venkatesha, M.B.A.
CEO of Vigilant Medical, Inc.
Santosh Venkatesha is the Founder & CEO of Vigilant Medical which is a Healthcare IT company developing smart medical imaging solutions. The first commercial product, ImageShare, focused on enhancing physician collaboration and decision making with a HIPAA compliant web-based application currently used by medical centers across the US and worldwide. Over 30,000 patients benefit from this technology each year. Recently, his focus has turned to use of machine learning techniques to improve cardiac image analysis and to aid physician interpretation. This work has been begun in collaboration with Duke University in 2018 as part of a successfully awarded NIH SBIR Phase 1 grant.
Prior to Vigilant Medical, Santosh was part of the management team of Infinite Biomedical Technologies from 1999 to 2009. He grew the company with the Johns Hopkins co-founders from startup to early stage starting from $300k to over $20M in funding. This company focused on translational research and development of medical diagnostics and devices in the application areas of cardiology, neurology, OB/GYN, GI, and upper limb amputees. This led to regulatory 510k approval for multiple products and eventual commercialization that continues today.
Santosh has a BSE in Biomedical Engineering from Duke University and a MBA from the Wharton Business School of the University of Pennsylvania.
VP & President-Elect of the Maryland HIMSS Chapter; Founder & CEO of STS Consulting Group, LLC.
Kathryn A. Whitmore, CEO of STS Consulting Group, founded the boutique strategy and transformation consultancy in 2011 to focus on healthcare analytics innovation driving population health outcomes and the industry transformation to value-based care. Kathryn is recognized as an analytics strategist, chief data officer, and population health thought leader.
She is the author of a unique ‘enterprise intelligence’ strategy and implementation model which leverages trusted data as the foundation for building cultures of accountability. This model has been proven to increase analytics maturity and drive transformation aligned with achieving the healthcare triple aim. To that end, Kathryn was honored to jointly receive The Data Warehousing Institute Best Practices Award for innovation as Cleveland Clinic’s solutions partner. Her results have also been recognized by a partner nomination for the SmartCEO Brava Award for high-impact business leaders.
Kathryn has been a member of the Healthcare Information Management and Systems Society (HIMSS) for many years actively serving in leadership roles for the Maryland Chapter since 2010. Currently, she is Vice President & President-elect of the Board of Directors. Her leadership was recognized with a National HIMSS Advocate of the Year award for her contribution to Maryland public policy advocacy including testimony to the Maryland Legislature for Senator Susan C. Lee sponsored telemedicine bills which later became law
Kathryn holds a Master of Science degree in Technical Program Management from the Johns Hopkins University Whiting School of Engineering. She also holds a Bachelor of Science degree in Computer Science and Information Management from West Chester University.
Companion Diagnostics & Biomarkers
Hassan A. Tetteh, M.D., MPA, MBA, FACS
Chief Medical Informatics Officer of the US Navy
Dr. Hassan Tetteh is a U.S. Navy Captain and Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and adjunct faculty at Howard University School of Medicine. Currently, Tetteh is a staff Thoracic Surgeon for MedStar Health and Walter Reed National Military Medical Center. He leads a Specialized Thoracic Adapted Recovery (STAR) Team, in Washington, D.C., and his research in thoracic transplantation aims to expand heart and lung recovery and save lives. Tetteh is board certified in thoracic surgery, general surgery, clinical informatics, and healthcare management, and is a Fellow of the American College of Surgeons and American College of Healthcare Executives
Justin Sacks, M.D., M.B.A.
Associate Professor of Plastic & Reconstructive Surgery, Director of Oncological Reconstruction
The Johns Hopkins University School of Medicine
Dr. Justin Sacks is an associate professor of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine. Dr. Sacks is an expert in head-to-toe reconstructive surgery of the body, including the head and neck, breast, chest, abdomen, pelvis and extremities. Among his specialties is reconstructive surgery following post-traumatic injury and oncologic surgery.
Dr. Sacks earned his M.D. from Mount Sinai School of Medicine and completed his residencies in plastic surgery and general surgery at Mount Sinai Medical Center. He performed fellowships in microsurgery at the University of Texas MD Anderson Cancer Center and in plastic surgery at the University of Pittsburgh Medical Center. Dr. Sacks comes to Johns Hopkins from a faculty appointment at the University of Texas MD Anderson Cancer Center.
His research interests involve modalities to induce donor-specific tolerance in composite tissue allograft constructs, such as the face and hand.
Dr. Sacks is certified in plastic surgery by the American Board of Surgery. He is an associate fellow member of the American College of Surgeons and a member of the American Society of Plastic Surgeons, American Society of Reconstructive Microsurgery and Plastic Surgery Research Council. Dr. Sacks is a founding member of the American Society of Reconstructive Transplantation.
Dr. Sacks was recently selected as a 125 Living the Hopkins Mission Honoree.
Edward Bessman, M.D., M.B.A.
Senior Director of Faculty Practice at The Johns Hopkins University School of Medicine
The Johns Hopkins University School of Medicine
A native of Boston, MA, Dr. Edward Bessman has been affiliated with The Johns Hopkins University since the age of 5. He received his undergraduate degree from Hopkins in 1977 and his medical degree from Harvard University and the Massachusetts Institute of Technology in 1981. After residency training in emergency medicine at the University of Maryland Medical System in 1985 he went into the community to practice emergency medicine as well as taking on a part-time faculty position with the Georgetown University Department of Emergency Medicine. He subsequently joined the emergency medicine faculty at the Johns Hopkins School of Medicine in 1992 with his clinical appointment at what was then the Francis Scott Key Medical Center, now Johns Hopkins Bayview Medical Center (JHBMC). He became Chairman of the Department of Emergency Medicine at JHBMC in 1997, and received his MBA in Medical Services Management from the Johns Hopkins Carey Business School in 2011.
Dr. Bessman’s interests include operations improvement, service excellence, and behavioral economics. He has scholarly publications regarding all phases of Emergency Department (ED) throughput, including triage, diagnosis, consultation, care management, admission and discharge. Under his guidance several innovative programs have been developed at JHBMC including a multidisciplinary combined inpatient/outpatient ED Observation Unit (1994), a credentialing pathway for ED point-of-care ultrasound (1999), a post-graduate residency in emergency medicine for Physician Assistants (2003) and a re-design of the admissions process with the Department of Medicine that has promoted throughput and patient safety and has been copied by many other institutions (2008).
In his role as Chairman he fostered an environment of innovation and collaboration that has made the JHBMC ED a preferred site for clinical investigation as well as for educational opportunities for learners from a variety of disciplines. In July of 2017, after leading the transition to new clinical space, Dr. Bessman stepped down as Chairman to take on a role as Senior Director of Faculty Practice across the academic division.
Dr. Bessman also performs Urban Search and Rescue operations with the Federal Emergency Management Agency as a member of Maryland Task Force-1. He is certified as a Confined Space Medical Specialist and as a Lead Instructor for the Confined Space Medical Specialist training curriculum. Notable deployments include the Oklahoma City bombing (1995), the attack on the Pentagon (2001) and Superstorm Sandy (2012). In his free time Dr. Bessman enjoys any outdoor activity on a board, training for triathlons, travel and experimenting with barbecue, smoking and sous-vide.
Dan Edelstein, M.B.A.
Director of Commercial Operations at Sysmex Inostics
Dan is the Vice President of Commercial Operations at Sysmex Inostics. He previously studied at Johns Hopkins and worked on early clinical studies of circulating tumor DNA in the laboratory Dr. Bert Vogelstein. While at Hopkins, he also described novel genotype-phenotype relationships and diagnostic approaches for hereditary cancer syndromes with Francis Giardiello. In 2011, Dan led the development of a CLIA laboratory for BEAMing ctDNA analyses, delivering the first commercial ctDNA assay for clinical practice and prospective clinical trials. Since then, he has worked on clinical utility evidence development, Biopharma partnering, market access and novel reimbursement pathways for ctDNA based assays to support the management of patients with cancer.
Drug Development & Targeted Therapies
Annastasiah Mudiwa Mhaka, PhD
Co-Founder Alliance for AI in Healthcare
Sr. Advisor, Adjuvant Partners
Dr. Mhaka is an experienced life sciences executive, investment professional, and biotech entrepreneur with a passion for global health. Leveraging expertise in biomedical discovery, technology development, healthcare delivery, and fundraising she creates transformative healthcare advances impactful on a global scale. Utilizing her experience in cross-disciplinary and multi-stakeholder approaches, Dr. Mhaka has co-founded the Alliance for Artificial Intelligence in (AAIH), a global organization dedicated to resolving the myriad challenges facing the growing field of Artificial Intelligence and Machine Learning based life sciences and healthcare solutions. In addition to her proven track record of over 50 cross-industry deals in both the private and public sector, she has co-founded four companies, and generated over $200 million in deliverables within the drug development and nanotechnology sectors. Dr. Mhaka received her PhD in Cellular and Molecular Medicine from Johns Hopkins Medicine where she developed a clinical phase oncology drug and attained her Bachelor of Science in Chemistry [Highest Honors, Summa Cum Laude] from the University of Pittsburgh.
Aiman Shalabi, PharmD
Vice President R&D, Cell and Gene Therapies (NYESO)
Aiman Shalabi is a global executive with over 20 years’ experience in developing and commercializing new medicines for patients with cancer. He currently leads the global development program for an adoptive cell therapy targeting solid tumors at GSK (NY-ESO TCR-T) that has achieved FDA Breakthrough and EMA PRIME designations. Previously Aiman was the Global Vice President at AstraZeneca leading the development team for durvalumab (anti-PDL1) from pre-clinical through phase III and then led the global medical affairs program to support the pre-launch of durvalumab. At MedImmune he led other IO programs such as the in-licensing and development of Tremelimumab (CTLA-4 from Pfizer) and OX40. Aiman is a leading advocate for external clinical/academic collaborations, and previously contracted with the Cancer Research Institute (CRI), the Canadian Cancer Trials group and the Harvard Business school to drive philanthropic support of academic clinical innovations.
Aiman entered the pharmaceutical industry after a successful career at the US National Institute of Health, National Cancer Institute (CTEP, PMB) where he managed a portfolio of 26 agents and led the NCI compassionate use program. He received a national award for providing patients with access to breakthrough medicines for leukemia (Gleevec) and breast cancer (Herceptin) prior to FDA approval.
Aiman has five university degrees including a Doctor of Pharmacy (USC) and an MBA (Johns Hopkins University).
Seasoned Biotech Executive, Former CEO of Altimmune (Most Recent),Former Executive Director at GenVec
William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Mr. Enright spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking it public. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities including the Head of Business Development. Mr. Enright has raised more than $300 million through private, public and non-dilutive financings.
Mr. Enright brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles.
Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
Daniel J. Durand, M.D.
Chief Innovation Officer at LifeBridge Health
Dr. Daniel J Durand, MD (“Dan”) is a physician executive with deep expertise in healthcare innovation, biomedical research, and value-based care.
Dr. Durand leads Innovation and Research for LifeBridge Health, a health system serving over 1 million patients with $2.5 B in revenue. Dan is accountable for overseeing all of LifeBridge’s projects, investments, and partnerships related to biomedical research, digital health, and value-based contracting. He also continues to practice medicine as the Chairman of Radiology for all four Lifebridge Health hospitals.
Over the course of his career, Dan has studied and served at the world’s leading medical organizations, including public, private, and academic institutions. His credibility as an executive is built upon a foundation of diverse but rigorous experiences in the sciences, clinical practice, general management, and entrepreneurship.
Dan’s writing has appeared in top journals such as The New England Journal of Medicine (NEJM) and the Journal of the American Medical Association (JAMA). He regularly lectures at national conferences on topics related to medical innovation.